Compliance Officer Pleads Guilty in Opioid Distribution Case

Miami-Luken Compliance Officer Pleads Guilty in Federal Opioid Distribution Investigation

James Schroering, former Chief Compliance Officer at Miami-Luken Inc., pleaded guilty on March 25, 2025, to conspiring to distribute controlled substances and failing to report suspicious orders of opioid pharmaceuticals. The plea marks the first criminal conviction of a wholesale drug distributor compliance officer under the Controlled Substances Act's suspicious order monitoring requirements, establishing direct personal liability for compliance personnel who fail to execute required diversion controls.

Regulatory Framework: Suspicious Order Monitoring Under 21 CFR 1301.74(b)

Wholesale drug distributors registered with the Drug Enforcement Administration are required under 21 CFR 1301.74(b) to design and operate a system to identify suspicious orders of controlled substances. The regulation, which has been on the books since 1971 but gained renewed enforcement focus during the opioid epidemic, requires distributors to:

1. Maintain effective controls against diversion of controlled substances into other than legitimate medical, scientific, and industrial channels
2. Report suspicious orders to the DEA and refuse to fill them
3. Establish order-monitoring systems that detect unusual size, frequency, or pattern of orders

The DEA defines a suspicious order as one of unusual size, orders that deviate substantially from a normal pattern, and orders of unusual frequency. Distributors are required to conduct due diligence on pharmacy customers and investigate when order patterns suggest potential diversion.

Between 2008 and 2015, Miami-Luken distributed more than 18 million doses of oxycodone and 13 million doses of hydrocodone to pharmacies in West Virginia, a state experiencing one of the nation's highest opioid overdose rates. The company shipped large volumes to pharmacies in small communities — in one instance, a pharmacy in a town of 1,400 people received 2.2 million doses over a two-year period.

Criminal Charges and Plea Agreement

The Department of Justice charged Schroering with conspiracy to distribute controlled substances (21 U.S.C. § 846) and failure to report suspicious orders (21 CFR 1301.74(b)). According to the plea agreement, Schroering:

• Received multiple DEA warnings about suspicious order patterns at customer pharmacies between 2013 and 2015
• Continued to approve shipments to pharmacies flagged by Miami-Luken's internal monitoring system
• Failed to report hundreds of suspicious orders to the DEA as required by regulation
• Instructed sales representatives to maintain relationships with high-volume pharmacy customers despite compliance red flags

The plea carries a maximum penalty of four years in prison and a $250,000 fine. Sentencing is scheduled for June 2025. Miami-Luken itself pleaded guilty in 2020 to failing to report suspicious orders and paid a $2.5 million fine. The company ceased operations in 2019.

Implications for Wholesale Distributor Compliance Programs

This case establishes criminal liability for compliance officers who knowingly fail to execute suspicious order monitoring requirements. Prior enforcement actions against wholesale distributors — including multimillion-dollar settlements with McKesson, Cardinal Health, and AmerisourceBergen — held corporate entities liable but stopped short of criminal charges against individual compliance personnel.

The Schroering prosecution signals that the DOJ will pursue individual accountability when compliance officers actively undermine required diversion controls. For wholesale drug distributors, this creates direct personal risk for compliance officers, quality assurance managers, and executives who approve controlled substance shipments.

Distributors registered with the DEA to handle Schedule II-V controlled substances must ensure their compliance officers have:

• Written authority to halt shipments flagged by order monitoring systems
• Direct reporting lines independent of sales or revenue functions
• Documented training on 21 CFR 1301.74(b) requirements
• Access to DEA reporting channels without executive approval requirements

The case also underscores the importance of responding to DEA warning letters and compliance inquiries. Schroering received multiple direct communications from the DEA regarding suspicious orders — continued shipments after regulatory notice formed the basis for criminal intent.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, of which 1,234 hold active FDA registration. DEA registration data — required for controlled substance distribution — is not yet included in ColdChainCheck's compliance scoring methodology. The directory has applied for access to DEA registrant data through the Regulatory Data Access (RDA) process, but approval timelines remain uncertain.

Of the entities tracked, 73 have at least one FDA enforcement action on record (recalls, warning letters, or import alerts). None of the current enforcement records in ColdChainCheck's database relate to DEA suspicious order violations, as those actions are housed in separate DOJ and DEA enforcement databases not systematically cross-referenced with FDA data.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. The score breakdown shows:

• 28 entities (2.2%) scored Excellent (80-100)
• 281 entities (22%) scored Good (60-79)
• 919 entities (72%) scored Fair (40-59)
• 38 entities (3%) scored Poor (20-39)
• 9 entities (0.7%) scored Minimal (0-19)

Compliance scores in ColdChainCheck measure publicly verifiable licensing, accreditation, and regulatory history. A Fair-tier score indicates basic state licensure and FDA registration but limited third-party validation (NABP accreditation, GDP certifications). Only 63 entities in the directory hold NABP accreditation — formerly the VAWD program — which includes enhanced diversion control requirements beyond baseline FDA standards.

Practical Guidance for QA and Procurement Teams

For compliance officers and procurement managers conducting due diligence on wholesale drug distributors:

• Verify DEA registration directly — Check the DEA's Diversion Control Division registrant search tool for any distributor handling controlled substances. ColdChainCheck does not yet track DEA registration status.
• Request suspicious order monitoring procedures — Ask distributors for written suspicious order policies, monitoring system documentation, and evidence of compliance officer independence from sales functions. The Schroering case demonstrates that stated policies mean little without operational enforcement.
• Review trading partner enforcement history — Use ColdChainCheck's directory to check for FDA enforcement actions, then cross-reference with DOJ's public database of corporate criminal prosecutions for controlled substance violations.
• Document compliance officer qualifications — When qualifying a new distributor, request resumes and training records for compliance personnel responsible for controlled substance order approval. Personal liability risk creates incentive for qualified oversight.

ColdChainCheck continues to monitor wholesale distributor enforcement actions. For regulatory updates and compliance guidance, see the Compliance Guides section.

Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. Entities should consult with qualified legal counsel and verify all regulatory requirements with the relevant authorities, including the DEA and FDA.